None listed
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: ? Signed written informed consent obtained prior to the study ? Men and women ? 19 years of age ? Eastern Cooperative Oncology Group(ECOG) Performance Status 0 ~ 2 ? Histologically confirmed colorectal adenocarcinoma ? Treatment naive patients scheduled to undergo 1L FOLFOX-based palliative chemotherapy ? Hb 8.0-11.0g/dL ? Life expectancy ? 3months
Exclusion criteria
Exclusion criteria: ? History of receiving iron supplements(oral or intravenous), erythropoiesis-stimulating agents(ESA), tranfusion, hemodialysis within 4 weeks ? Any severe infection within 28 days prior to study start ? Ongoing bleeding ? Bone marrow infiltration by the cancer ? Serum AST and ALT ? 3.5 * upper limit of normal(ULN) ? Hypersensitivity to ferrous sulfate ? Anemia other than iron-deficiency anemia ? Patients with ron overload(Ferritin > 800ng/ml, Transferrin saturation ? 50%) or disorders of iron metabolism ? Pregnancy or Breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Analysis of the diversity and composition of the gut microbiome by 16S rRNA sequencing | — |
Secondary
| Measure | Time frame |
|---|---|
| The change of hemoglobin;The mean change of Fe, Ferritin, TIBC;Analysis of the change of gut and systemic metabolome;Treatment-related adverse events graded according to NCI CTCAE version 5.0.;Quality of life assessed by EORTC QLQ-C10 | — |
Countries
Korea, Republic of
Contacts
Korea University Anam Hospital